The 3rd episode of Israel’s Weizmann in Focus, highlights that, since October, 7.3 million Americans have been sick with the flu virus with over 80,000 hospitalized. Weizmann Professor Ruth Arnon’s work has led to the development of the Universal Flu … Continue reading →

The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is sponsoring a US-wide Phase 2 trial of the M-001 Universal Flu vaccine from Israel’s BiondVax.  A 9,630-person, EU-financed Phase 3 trial … Continue reading →

The European Investment Bank has granted a 20 million Euro loan to Israeli biotech BiondVax to fund the Phase III trials of its Universal Flu Vaccine. http://www.globes.co.il/en/article-20m-eu-loan-to-fund-biondvax-phase-iii-trial-1001193180

Israel’s BiondVax has published independent tests of trials showing that its M-001 Universal Flu vaccinations given 3 years ago have protected patients from flu strains that only came into existence well after the vaccine was administered. http://www.biondvax.com/2015/08/03/independent-results-show-that-biondvaxs-universal-flu-vaccine-administered-in-a-trial-3-years-ago-improves-immunogenicity-against-current-flu-h3n2-epidemic/

The reasons for Israel’s high vaccination rate include universal healthcare, loyalty to health funds, focus on prevention, experience with emergencies and flu vaccines, secure access to patient medical records, hi-tech systems, publicity about vaccine availability and a willing public. https://www.jpost.com/health-science/nine-reasons-why-israel-leads-the-world-in-vaccine-distribution-654160